MedTrace Logo

Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus

NCT01079195 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15436

Last updated 2011-05-09

Study results available
· View outcomes & findings →

Summary

The aim of this post-marketing observational study (PMOS) is to provide data on the effectiveness and tolerability of Tarka in patients with a high risk of developing diabetes mellitus, as prescribed by the physicians in a community setting and in accordance with the terms of the local marketing authorization. The following specific questions will be addressed:

* Effectiveness of Tarka in lowering the blood pressure in hypertensive patients being at high risk of developing diabetes, not controlled on single-drug therapy.
* Tolerability of Tarka as assessed by withdrawal rates.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Cornelia Preda, MD · Abbott International

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Bulgaria
  • Czechia
  • Romania
  • Russia
  • Slovakia
  • Slovenia
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01079195 on ClinicalTrials.gov